Clinical Diagnostic Lab
Total Trials
29
As Lead Sponsor
22
As Collaborator
7
Total Enrollment
1,058
NCT00463450
Efficacy of Gynodian® Depot in Women With Impaired Well-being
Phase: Phase 3
Role: Collaborator
Start: May 31, 2002
Completion: Apr 30, 2004
NCT01153854
Safety, Efficacy and Cost-effectiveness of Racecadotril in Children With Acute Diarrhea in Mexico
Start: Jan 31, 2007
Completion: Dec 31, 2009
NCT03232619
CD19-CART Treatment for ALL
Phase: Phase 1/2
Role: Lead Sponsor
Start: Aug 1, 2018
Completion: Sep 15, 2020
NCT05100277
Impact of Oncotype DX® on Treatment Recommendation and Its Economic Evaluation Under the Brazilian Society Perspective
Phase: N/A
Start: Aug 8, 2018
Completion: Feb 4, 2019
NCT03229876
Safety and Efficacy Evaluation of CD19-UCART
Start: Jun 1, 2019
Completion: Dec 30, 2023
NCT03752541
Efficacy and Safety Evaluation of BCMA-UCART
Start: Nov 1, 2019
Completion: Nov 20, 2023
NCT04213469
PD1-CD19-CART in Patients With r/r B-cell Lymphoma
Start: Mar 13, 2020
Completion: Nov 10, 2023
NCT04053062
LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer
Phase: Phase 1
Start: Jul 16, 2020
Completion: Oct 15, 2024
NCT04211480
Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells
Start: Oct 1, 2020
Completion: Nov 27, 2023
NCT03492268
Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma
Start: Nov 1, 2021
Completion: Dec 31, 2024
NCT04205435
β-globin Restored Autologous HSC in β-thalassemia Major Patients
Completion: Jul 25, 2022
NCT04768608
PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer
Start: Dec 23, 2021
Completion: May 30, 2023
NCT05577312
Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia
Start: Nov 1, 2022
Completion: Sep 10, 2026
NCT06314529
Long-term Follow-up Study of BHC001 for TDT
Start: Dec 14, 2022
Completion: May 10, 2037
NCT05741359
The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
Start: Apr 25, 2023
Completion: Mar 15, 2024
NCT05859997
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
Start: May 17, 2023
Completion: May 27, 2025
NCT05988216
Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus
Start: Aug 14, 2023
Completion: Sep 30, 2025
NCT05381181
Safety and Efficacy Evaluation of Next-generation CD19-UCART
Start: Dec 20, 2023
Completion: May 3, 2026
NCT05442346
Start: Dec 25, 2023
Completion: Nov 30, 2024
NCT05308875
Efficacy and Safety Evaluation of PD1-BCMA-CART
Start: Mar 1, 2024
Completion: Oct 1, 2025
NCT06228404
Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC
Phase: Early Phase 1
Start: Mar 3, 2024
Completion: Dec 31, 2025
NCT06287099
Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease
Start: Apr 20, 2024
Completion: May 10, 2026
NCT06287086
Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease
Start: Jun 14, 2024
Completion: Jun 10, 2026
NCT06300723
Clinical Study of BRL-101 in Severe SCD
Start: Jul 29, 2024
Completion: Jun 15, 2026
NCT06633042
The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD
Start: Nov 25, 2024
Completion: Dec 12, 2025
NCT06681337
Universal CAR-T Cell Therapy for Refractory Lupus Nephritis
NCT06298630
Long-term Follow-up Study of BRL-101 for TDT
Start: Dec 8, 2024
Completion: Oct 15, 2038
NCT06485232
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
Start: Feb 28, 2025
Completion: Dec 31, 2027
NCT06895811
Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC
Start: Mar 27, 2025
Completion: Nov 30, 2025
Loading map...